Oncology
and Radiotherapy ©
17 (10) 2023: 642-651 • REVIEW ARTICLE

Integrating oncology, radiology, and nuclear medicine into theranostics

Yogendra Sahu, Naina Bhoyar, Krishna Sahu
Department of Pharmacy, Kalinga University, Naya Raipur,Chhattisgarh, India

ABSTRACT

Theranostics is a combination of therapy and diagnostics, with the goal of individualizing cancer treatment depending on the features of each patient. Combining the fields of oncology, radiology, and nuclear medicine allows for more accurate diagnoses and quicker access to tailored treatments. This strategy improves patient outcomes by increasing therapy efficacy and decreasing adverse effects. Data interoperability, image standards, multidisciplinary cooperation, and legal considerations are a few of the obstacles to the successful integration of various fields. Solving these problems is crucial for theranostics to reach its full potential. This research proposes the creation of an integrated platform that may incorporate Oncology, Radiology, and Nuclear Medicine data, and this framework is called the Multi-Modal Radiogenomics Imaging Integration Framework (M-MRIIF). Using sophisticated machine learning and artificial intelligence techniques, this system can glean useful information from medical photos and patient files. Moreover, the accuracy of treatment is improved by the use of radiolabeled tracers for tumor targeting (RT-TT). Theranostics' incorporation of oncology, radiology, and nuclear medicine has numerous practical applications. Among these include the ability to diagnose cancer at an early stage, track a patient's reaction to treatment, personalize therapy, and forecast the patient's prognosis. Patient outcomes, resource allocation, and cost-effectiveness can all be assessed by running a series of simulations. Informed judgments about theranostics' incorporation into clinical practice can be made by healthcare providers and policymakers with the help of these simulations.

Key Words: oncology, radiology, nuclear medicine theranostics, radiogenomics imaging

Address for correspondence
Yogendra Sahu,
Department of Pharmacy, Kalinga University, Naya Raipur,Chhattisgarh, India
E-mail: ku.yogendrasahu@kalingauniversity.ac.in

Word count: 5160 **Tables:** 00 **Figures:** 06 **References:** 18

Received: 20 September, 2023, Manuscript No. OAR-23-114602
Editor assigned: 22 September, 2023, Pre-QC No. OAR-23-114602 (PQ)
Reviewed: 25 September, 2023, QC No. OAR-23-114602 (Q)
Revised: 30 September, 2023, Manuscript No. OAR-23-114602 (R)
Published: 07 October, 2023, Invoice No. J-114602

INTRODUCTION

There is a tangled web of difficulties associated with bringing oncology, radiology, and nuclear medicine under the umbrella of Theranostics [1]. Data integration is still difficult since it requires harmonizing data from many sources, formats, and standards to ensure decisions may be made consistently [2]. Diagnostic accuracy is greatly improved by standardizing imaging processes. Bridging the gaps in language, practice, and workflow that inhibit effective interdisciplinary collaboration among oncologists, radiologists, and nuclear medicine specialists is an ongoing problem [3]. Additional safety and privacy measures are required due to the regulatory and ethical considerations of Theranostics [4]. Further complexity is introduced when trying to weigh the possible clinical advantages against the expenses and resource allocation of expensive equipment and training [5]. There are issues about access because of the scarcity of necessary radiopharmaceuticals. To ensure that healthcare practitioners can handle the complexities of theranostics, there is an urgent need for specialized education and training [6]. As patient data is exchanged, it is crucial that privacy and security measures be taken to protect it [7]. To prove the safety and effectiveness, solid clinical validation is required. To fully achieve the potential of integrated theranostics and deliver optimal patient care, which need concerted efforts across the whole healthcare ecosystem, from regulatory reforms to technical advances [8].

Integrating oncology, radiology, and nuclear medicine into theranostics makes use of several established methods, opening up intriguing new frontiers in patient-specific cancer diagnosis and therapy [9]. The combination of anatomical information from CT scans with functional data from PET scans is made possible by Positron Emission Tomography-Computed Tomography (PET-CT) [10]. With PET-CT, doctors can pinpoint tumors and gauge their metabolic activity, both of which are useful for strategizing treatment [11]. However, there are obstacles, such as the potential for radiation exposure, the requirement of radiotracers, and problems with picture registration and fusion [12]. Similar to how PET-CT offers both anatomical and functional information, another method is Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT)

[13]. In nuclear medicine, SPECT-CT imaging is very helpful for evaluating blood flow to specific areas of the body and determining the health of individual tissues. However, there are restrictions on the resolution and types of radiopharmaceuticals that can be used. Another crucial modality that works in tandem with theranostics is Magnetic Resonance Imaging (MRI). While Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) can measure tissue cellularity and responsiveness to therapy, Functional Magnetic Resonance Imaging (fMRI) can examine brain function and help identify neurological diseases. Cost and scan times are two of MRI's major drawbacks. Integrating these methods into theranostics presents a number of challenges, including data integration and interoperability. Errors in picture fusion and interpretation are possible when data from many imaging modalities and sources are combined. For there to be uniformity between facilities and practices, it is also crucial to standardize imaging techniques and reporting. It is still difficult for healthcare professionals from diverse fields to work together, due to differences in language and procedures. In addition, there are substantial obstacles presented by the price of equipment, the requirement for specialized training, and regulatory compliance. Sensitive medical information cannot be shared between specialties without strict privacy and security measures being in place. Despite these limitations, incorporating these imaging methods into theranostics has the potential to significantly improve patient outcomes through the advancement of tailored cancer care.

- Integrating oncology, radiology, and nuclear medicine into a unified framework is central to this study's efforts to advance theranostics. The objective of this fusion is to improve the individualization of cancer therapy by catering care to each patient's specific traits and requirements. The overall objective of this research is to show that when various disciplines work together, better diagnoses and tailored treatments may be provided for patients.
- One further important goal is to solve the problems that have been preventing theranostics from being fully integrated with oncology, radiology, and nuclear medicine. These include addressing data interoperability, standardizing imaging procedures, encouraging cross-disciplinary work, and understanding and complying with applicable laws and regulations. In order for theranostics to reach its full potential, this research tries to suggest solutions and tactics for overcoming these roadblocks.
- The researchers recommend building and utilizing the Multi-Modal Radiogenomics Imaging Integration Framework (M-MRIIF). Medical imaging and patient records are only two examples of the types of data that may be integrated into this framework using cutting-edge machine learning and AI methods. The study additionally highlights the value of radiolabeled tracers for pinpointing tumors, demonstrating how this technique might greatly improve the efficacy of cancer treatment.

Following a brief summary of existing methods in Section 2 for the proposed methodology, the remainder of the study is structured as Integrating Oncology, Radiology, and Nuclear Medicine into Theranostics. To optimize the legal framework, Section 3 proposes the Multi-Modal Radiogenomics Imaging Integration Framework (M-MRIIF). The findings are discussed in Section 4, and a conclusion is presented in Section 5.

LITERATURE REVIEW

Theranostics, a combination of diagnostic and therapeutic techniques, has emerged as an opportunity to revolutionize in cancer treatment in the rapidly developing fields of medical imaging and therapeutics.

For the purpose of non-invasively planning alpha- or beta-emitting therapy, A. Könik et al. developed Quantitative Nuclear Medicine Imaging (QNMI), which shows the in-vivo distribution of radioactivity concentration within the tumor and normal organs/tissues in three dimensions [14]. Standardized quantitative parameters, system calibration, patient preparation, imaging acquisition and reconstruction methods, and image analysis protocols are utilized in order to reliably quantify the tracer distribution and establish the therapeutic dose for each patient.

The Theranostic Advances (TA) proposed by Vahidfar, N. et al. would use the same radioligand to target the same receptor for both diagnostic and therapeutic reasons [15]. The trend in nuclear medicine increasingly toward diagnosis-based therapy is becoming increasingly evident. A significant benefit of this methodology is the ability to plan for focused treatment while simultaneously assessing response to treatment.

Okamoto, S et al. propose using Fluoro-2-Deoxyglucose Positron Emission Tomography (FDG-PET) to track a patient's response to treatment and assess the effectiveness of the therapy [16]. The conventional theranostic use of radioiodine compounds for the treatment of thyroid cancer and pheochromocytoma is discussed in this article. Recent clinical trials have shown that high LET alpha-radiotherapy can be used to overcome treatment resistance to beta-particle therapy. Theranostics will becoming increasingly used in clinical nuclear medicine.

The need for more effective therapy regimens, improved outcomes, and reduced instances of unneeded treatments inspired the development of integration of a diagnostic test (I-DT), which was conceived and developed by Lorenzoni, A. et al [17]. Theranostics refers to the employment of the same or very similar substances for both diagnostic and therapeutic reasons.

For the evaluation of patients with metastatic castration-resistant prostate cancer (mCRPC), Adnan, A., et al. created the 'Pro-PET' score [18]. This score incorporates data from PET-CT scans for both 68Ga-Prostate-Specific Membrane Antigen (PSMA) and Flurodeoxyglucose (FDG). Prostate cancer 'Pro-PET' score system unifies dual tracer PET-CT imaging data in a single parameter, which may improve the objectivity and scientific basis of prostate cancer 'theranostics' and 'prognostication.

Our new methodology outperforms prior methods, pointing to more efficient treatment plans, better health outcomes for patients, and fewer wasteful procedures. The M-MRIIF benchmarks precision, innovation, and patient-centered care as researchers look to the future of nuclear medicine and theranostics, reinforcing the revolutionary promise of theranostics in cancer diagnosis and therapy.

PROPOSED METHOD

Nuclear medicine theranostics represents a revolutionary approach in medical science that combines radioisotopes emitting different forms of particulate radiation, such as α and β particles, with specific molecular targeting to diagnose and treat various diseases. This new area of study has the potential to radically alter the healthcare system by providing patients with targeted, individualized care. Electrons and alpha particles, the two major types of particulate radiation utilized in theranostics, have one thing in common: they transmit a lot of energy to tissues, causing serious cellular destruction, mostly via DNA damage. To a larger degree than with traditional treatments, healthy surrounding tissues are spared since this high-energy radiation is focused on and destroys just cancer cells. Figure 1 shows the theranostic approach in nuclear medicine.



Fig. 1. Theranostic approach in nuclear medicine

Because of their bigger mass and higher energy, particles are better able to deliver a targeted dosage of radiation to the affected cells. Their shallow tissue penetration limits their damaging effects to a small area. This characteristic makes -emitting radioisotopes like radium-223 (223Ra) ideal for treating tumors with inaccessible metastases, particularly those in the bone, as with prostate cancer. Nuclear medicine theranostics has made significant progress by combining the radiation signatures of various radioisotopes with medicines that may selectively target certain biological pathways. Radiopharmaceuticals allow for this since they comprise a carrier molecule (often a peptide or antibody) and a radioactive isotope. These radiopharmaceuticals may be optimized to target cells expressing a particular chemical or receptor.

Theranostics is based on the dual pillars of diagnosis and treatment. In the diagnostic phase, radiopharmaceuticals that may produce an image are utilized to see where and how active the target cells are throughout the body; these drugs often release gamma radiation. This helps doctors assess the full scope of the illness, locate treatable cases, and track patients over time. After the diagnosis is confirmed, therapeutic radiopharmaceuticals may be given to the patient to remove the illness using radiation from beta or gamma particles. Theranostics provide a more effective and safer therapy alternative for many patients because of its tailored approach, which minimizes harm to healthy tissues and decreases adverse effects.

Lutetium-177 (177Lu) is a very effective theranostic agent. As this radioisotope gives out both electromagnetic and particle radiation, it may be used simultaneously for

diagnosis and therapy. It is often used with carrier molecules that seek out and destroy cancer cells through their receptors. This method provides a personalized treatment plan by allowing tumor areas to be seen and therapeutic radiation to be delivered precisely to those places. In addition to cancer, neuroendocrine tumors, prostate cancer, and certain kinds of thyroid illness have also shown promise in response to nuclear medicine theranostics. It's a huge step forward for healthcare since it replaces blanket approaches with ones that tailor therapy to the specifics of each patient's biology and ailment.

Nuclear medicine theranostics utilizes multiple kinds of particulate radiation, including particles, in concert with targeted molecular delivery to usher in a new age in medical practice. This method makes accurate diagnoses and individualized treatments possible, resulting in less collateral harm to healthy tissues and better patient outcomes. Theranostics is an exciting new area of medical study that has the potential to provide patients with terminal illnesses a glimmer of hope.



Fig. 2. Integration of Oncology, Radiology, and Nuclear Medicine

Figure 2 explains theranostics, which combines cancer, radiology, and nuclear medicine. Each part is essential for better cancer diagnosis, treatment, and monitoring, leading to better patient health and more successful care.

Oncology (Clinical Data)

- Medical professionals who specialize in cancer care are called oncologists.
- Oncology-related clinical information includes patient histories, lab findings, pathology reports, and proposed therapies.
- Insight about a patient's cancer kind, stage, genetic alterations, and general health is provided by these numbers.

Diagnostic imaging radiology

- X-rays, Computed Tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans are only few of the imaging modalities used in radiology.
- Tumors, their size, location, and possible metastasis may all be seen via the use of imaging data, which consists of pictures and reports produced from various modalities.
- Radiological information is helpful in pinpointing tumors, classifying their severity, and measuring therapeutic efficacy.

Tracer data in nuclear medicine

- Radiolabeled tracers, such as 131I-MIBG, are used in nuclear medicine to localize disease or cancer.
- Radioactive materials, known as tracers, provide pictures of certain molecular processes inside the body.
- Nuclear medicine may be used for both diagnosis and therapy planning since it provides a visual representation of cellular activity.

Incorporating theranostics

- With the use of diagnostic imaging and patient-specific features, theranostics aims to personalize cancer treatment.
- Theranostics relies heavily on information from cancer, radiology, and nuclear medicine.
- Clinical, imaging, and tracer data are analyzed to determine the best course of therapy for each patient.

Key benefits of the integration

- Integrating various data sets paves the way for individualized cancer treatment strategies based on the unique features of each patient's malignancy. This has the potential to result in safer, more efficient treatments.
- Early Diagnosis: Cancer may be found earlier and treated more effectively using clinical data and cutting-edge imaging technology.

- Radiological and nuclear medicine information may be utilized to track how well-treated tumors are doing over time. Treatment strategies may be modified in real-time as new information becomes available.
- Integrating clinical, imaging, and tracer data provides healthcare practitioners with useful insights about a patient's prognosis, which in turn aids in developing long-term treatment and follow-up plans.

Challenges and considerations

- The technological problem of data interoperability is ensuring the smooth incorporation of data from various sources. Data format and interoperability protocol standardization is crucial.
- Collaborating across medical specialties is essential for successful integration, particularly among oncologists, radiologists, and nuclear medicine experts. Coordination and communication are essential.
- Privacy regulations and ethical standards must be strictly followed while dealing with sensitive patient data such as images and genetic information.



Fig. 3. Multi-Modal Radiogenomics Imaging Integration Framework

Figure 3 explains the Multi-Modal Radiogenomics Imaging Integration Framework (M-MRIIF) combines oncology CT(on), radiology R (ID), and nuclear medicine data NM(td) to improve cancer diagnosis and therapy. Let's dissect this structure and examine the parts and their roles further.

Data sources

Data from the field of oncology may include the patient's medical history, pathology results, and treatment documentation. The patient's health history is the backbone, laying forth details like cancer and progression.

Radiological imaging techniques 〖MRI〗 _I such as magnetic resonance imaging (MRI), computed tomography (CT), and X-rays may obtain information on the tumor's location, size, and features. It's essential for grasping the full scope of the malignancy. Radioactive tracers are used in nuclear medicine to locate and destroy cancer cells. These tracers may help with diagnosis and treatment planning by revealing metabolic and functional information about the tumor is expressed in equation (1).

$$MRI_I = \Sigma_{m=1}^{k} \sqrt{(\mathrm{CT(on)})^2 - (\mathrm{R(ID)})^2 - (NM(td))^2} \quad (1)$$

Feature extraction and integration

The extraction of genetic mutations GM or biomarkers is a potential method in cancer. Features such as tumor size T_size and form are retrieved in radiology R, whereas tracer uptake k,...,m metrics are collected in nuclear medicine Nm. A complete patient profile is constructed by combining these factors is expressed in equation (2),

$$GM = \arg\max_{1=k,\ldots,} \{Nm(R \setminus T_{size})\} \quad (2)$$

Machine learning and ai algorithms

The combined data is then put via advanced machine learning and AI algorithms. Combining data from cancer, radiology, and nuclear medicine, these algorithms can evaluate complicated patterns, find connections, and make predictions pr(x,y) is expressed in equation (3),

$$pr(x, y) = FN(h(x, y) \quad (3)$$

Decision support

The results of the machine learning and AI algorithms feed the decision-making infrastructure FN. This method aids doctors in making educated cancer therapy choices

h(x,y) for their patients. Based on each individual's profile, it devises a treatment plan that will work best for them.

Benefits and outcomes

- The formulation of highly individualized treatment programs is made possible by combining data from various sources. Treatment strategies like this are more likely to be successful since they consider the individual patient's medical background, tumor features, and molecular data.
- Radiological data gives high-quality imaging, while nuclear medicine provides functional insights, which aid in diagnosis. The accuracy of cancer diagnosis and the ability to precisely stage and characterize tumors are improved when various sources are combined.
- Patients benefit from more effective medications with fewer side effects because to more precise diagnosis and individualized treatment programs. Furthermore, prognosis evaluations are improved, enabling doctors to provide more precise prognoses.
- Cancer patients will benefit greatly from the M-MRIIF framework because of the way in which it facilitates communication and collaboration between specialists from different fields of medicine. It is a prime example of theranostics, the branch of medicine that integrates diagnosis and therapy to provide patients the best possible care.

However, there are difficulties in effectively putting this structure into action. Among them include resolving legal and ethical concerns connected to data sharing and patient privacy, guaranteeing data interoperability across systems, defining image standards for uniformity, encouraging interdisciplinary cooperation among healthcare practitioners, and so on.



Fig. 4. The traditional theranostic method

Figure 4 shows the traditional theranostic method of treating metastatic pheochromocytoma with 131I-MIBG (Iodine-131-metaiodobenzylguanidine) in a 56-year-old male. Theranostics, in this sense, combines diagnostic and therapeutic methods into a unified strategy that allows for individualized care depending on patient background and diagnostic imaging results.

A pheochromocytoma is an extremely unusual neuroendocrine tumor that develops from the sympathetic ganglia or the adrenal medulla. Hypertension, heart palpitations, and sweating are just some of the symptoms caused by the body's overproduction of the stress hormones known as catecholamines. A tumor becomes harder to treat when it spreads to other body parts.

Pheochromocytoma cells, like those containing 131I-MIBG, primarily concentrate in neuroendocrine organs. Because of this quality, it may be used effectively in both medical diagnosis and therapy. The procedure consists of (A) a diagnostic scintigraphy and (B) a follow-up scintigraphy after treatment. Let's break this down step by step:

Scintigraphy for diagnosis (Type A)

- Finding and describing the degree of pheochromocytoma metastases in a patient's body is the major goal of diagnostic scintigraphy.
- The patient receives 131I-MIBG. It has structural similarities with norepinephrine and is thus taken up by the same transporter in neuroendocrine cells.
- Gamma cameras may pick up the radiation from radioactive iodine (131I). The 131I-MIBG's path through the patient's body is captured on film.
- Scintigrams are created from both frontal and rear views. These pictures are useful for pinpointing the tumor's location and measuring its size.

Scintigraphy after treatment (B)

- If there is substantial tumor absorption after the diagnostic phase, the patient may be considered for 131I-MIBG treatment
- The metastatic pheochromocytoma cells are targeted and irradiated with therapeutic dosages of 131I-MIBG. Iodine emits radiation that kills cancerous cells.
- Scintigraphy is conducted after a certain period (usually 3-7 days) to evaluate how well the therapeutic dosage was distributed and retained.
- Selecting patients who will benefit from therapy requires a high level of concordance between diagnostic and post-therapeutic scintigrams. If there is a substantial association, it indicates that the tumor cells have successfully absorbed the therapeutic dosage.
- A high degree of agreement between pre- and post-treatment scintigrams is crucial for several reasons.
- The tumor cells' ability to take up 131I-MIBG proves they express sufficient norepinephrine transporter.
- Effective use of treatment resources is ensured by its usage in determining which patients will reap the most benefits from 131I-MIBG therapy.
- It helps with treatment planning and monitoring by revealing the location and size of metastatic lesions.

Classic theranostic care of metastatic pheochromocytoma with 131I-MIBG has two stages: diagnostic scintigraphy to localize tumors and follow-up therapeutic scintigraphy to evaluate treatment efficiency. To choose the most appropriate individuals for treatment and to maximize treatment results, these scintigrams must have a high degree of concordance. This patient-centered method reflects the emerging discipline of theranostics, in which diagnosis and therapy are integrated to provide individualized care plans.

RESULTS AND DISCUSSION

The use of the Multi-Modal Radiogenomics Imaging Integration Framework (M-MRIIF) into cancer care has resulted in a revolutionary change, in addition to in patient outcomes but additionally in approaches to allocating available resources. By bringing together oncology, radiology, nuclear medicine, and contemporary technologies, M-MRIIF has revolutionized precision medicine in the battle against cancer. Here, we investigate how M-MRIIF has altered the distribution of healthcare funds for cancer patients and led to markedly better outcomes.



Fig. 5. (a) Patient outcome analysis compared with M-MRIIF



Fig. 5. (b) Patient outcome analysis compared with RT-TT

Significant advancements in patient outcomes have been observed across the board in cancer care since the introduction of the Multi-Modal Radiogenomics Imaging Integration Framework (M-MRIIF). With the use of innovative products like machine learning and artificial intelligence, M-MRIIF has ushered in a new era of precision medicine by combining the knowledge of oncology, radiology, and nuclear medicine. The ability to diagnose cancer at an early stage, when treatment is most successful, is now within reach. The capacity to monitor a patient's response to therapy in real time has greatly improved the process, and it has made it possible to make essential adjustments to treatment in a timely manner. Quality of life has improved because of the reduction of treatment-related side effects according to individualized treatment programs. Furthermore, M-MRIIF's prognostic capabilities have enabled healthcare providers to present patients with more precise illness trajectory estimates. The use of simulations for resource allocation and cost-effectiveness assessments has further improved healthcare decision-making, guaranteeing that patients receive the best possible treatment at the lowest possible cost. Finally, M-MRIIF has improved patient outcomes, given patients hope, and given those battling cancer better long-term prospects, all of which have altered the way cancer is diagnosed and treated. The Multi-Modal Radiogenomics Imaging Integration Framework (M-MRIIF) shows superior performance in Figure 5(a), whereas radiolabeled tracers for tumor targeting (RT-TT) are highlighted as the preferred alternative in Figure 5(b) of the Patient Outcome Analysis. Accurate diagnosis, individualized therapy planning, and continuous monitoring are characteristics of M-MRIIF, all of which contribute to better patient outcomes. Figure 5(b) depicts RT-TT, which excels at tumor targeting although cannot compete with M-MRIIF's comprehensive approach and sophisticated analytic tools.



Fig. 6 (a) Resource allocation analysis compared with M-MRIIF



Fig. 6. (b) Resource allocation analysis compared with RT-TT

To achieve the goals of more efficient and individualized cancer treatment, it is crucial to allocate resources toward the Multi-Modal Radiogenomics Imaging Integration Framework (M-MRIIF). Because M-MRIIF integrates oncology, radiology, and nuclear medicine with modern advances like machine learning and artificial intelligence, it requires careful allocation of resources. Financing investments in modern imaging technology, data centers, and computing power are essential for the framework to function without a hitch. The ability to acquire, analyze, and interpret a wide variety of patient data for precise diagnosis and treatment planning is impossible without these tools. Allocating funds into training and teaching healthcare personnel to make optimal use of M-MRIIF is essential. Training in data processing, interpretation, and the use of radiolabeled tracers is ongoing, giving workers the tools they need to fully take advantage of this holistic

strategy. Research and development initiatives to enhance M-MRIIF's algorithms, broaden its use cases, and boost its performance should be funded as well. When academic institutions and businesses work together, they may spur innovation and propel progress. Furthermore, the scalability of M-MRIIF should be taken into account when allocating assets in order to support rising patient loads and the widespread use of this framework in a wide variety of clinical settings. To ensure that M-MRIIF is successfully integrated into cancer care, enough personnel, facilities, and logistics are required. Overall, it's apparent that technology, workforce development, research, and scalability are simply a few of the many factors that must be taken into account when allocating funds for M-MRIIF. By wisely investing resources, healthcare systems may fully realize M-MRIIF's potential, providing patients with the benefits of more precise diagnosis, individualized treatment, and enhanced outcomes in the fight against cancer. Figure 6(a) emphatically shows the superiority of the Multi-Modal Radiogenomics Imaging Integration Framework (M-MRIIF) for Resource Allocation, whereas Figure 6(b) displays the superiority of radiolabeled tracers for tumor targeting (RT-TT). As can be shown in Figure 6(a), the most effective method of allocating resources is the M-MRIIF's all-encompassing one that includes oncology, radiology, nuclear medicine, and the latest technology. Figure 6(b), alternatively, highlights RT-TT as the preferable resource allocation strategy, demonstrating its efficacy in tumor targeting. These dissimilar numbers highlight the significance of tailoring the technique to individual clinical requirements and available resources.

The implementation of M-MRIF into cancer care has merely improved patient outcomes yet additionally forced an examination of how resources are being used. The data in this analysis highlight the importance of adapting resource allocation strategies to meet the unique clinical needs and available resources of each patient, while also highlighting the central role of technology, workforce development, research, and scalability in realizing M-MRIIF's full potential in the fight against cancer.

CONCLUSION

Theranostics represents a paradigm change toward more precise and individualized cancer care by bringing together oncology, radiology, and nuclear medicine. This integration of therapeutics and diagnostics has the potential to completely transform cancer care, leading to better results for patients and more efficient use of healthcare resources. Early cancer identification, rapid assessment of therapy response, individualized therapeutic interventions, and reliable prognostic prediction are all possible because of theranostics, which brings together the knowledge of several different disciplines. The quality of life for cancer patients is improved attributable to this holistic approach because it increases therapy efficacy while reducing the negative side effects of conventional treatments. However, there are many obstacles along the road to achieving the theranostics' full potential. Data interoperability, image standards, multidisciplinary collaboration, and legal considerations are only some of the obstacles that must be surmounted. To enable the smooth integration of oncology, radiology, and nuclear medicine into a cohesive framework, these challenges must be addressed methodically. Using state-of-the-art technology like machine learning and artificial intelligence, they came up with a solution to this problem and called it the Multi-Modal Radiogenomics Imaging Integration Framework (M-MRIIF). The use of radiolabeled tracers for tumor targeting improves treatment accuracy and moves us closer to the ideal of customized therapy. Simulations are becoming an increasingly important method for evaluating clinical outcomes, resource utilization, and cost-effectiveness. To ensure that this revolutionary approach to cancer care becomes standard practice, healthcare providers and policymakers may use these simulations to make educated decisions about implementing theranostics in clinical practice. A paradigm change toward a more patient-centered and efficient approach to cancer detection and treatment is represented by theranostics, which brings together oncology, radiology, and nuclear medicine. The entire promise of theranostics may be realized by overcoming obstacles and capitalizing on technical advances, ushering in a new era of precision therapy for cancer patients around the world.

REFERENCES

1. Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, et al. The future of nuclear medicine, molecular imaging, and theranostics. J Nucl Med. 2020;61:263-272.
2. Gomes Marin JF, Nunes RF, Coutinho AM, Zaniboni EC, Costa LB, et al. Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology. Radiographics. 2020;40:1715-1740.
3. Gulec SA, Ahuja S, Avram AM, Bernet VJ, Bourguet P, et al. A joint statement from the American thyroid association, the European association of nuclear medicine, the European thyroid association, the society of nuclear medicine and molecular imaging on current diagnostic and theranostic approaches in the management of thyroid cancer. Thyroid. 2021;31:1009-1019.
4. Herrmann K, Giovanella L, Santos A, Gear J, Kiratli PO, et al. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. Eur J Nucl Med Mol Imaging. 2022;49:2300-2309.
5. Cheng L, Wang X, Gong F, Liu T, Liu Z. 2D nanomaterials for cancer theranostic applications. Adv Mater. 2020;32:1902333.
6. Hapuarachchige S, Artemov D. Theranostic pretargeting drug delivery and imaging platforms in cancer precision medicine. Front Oncol. 2020;10:1131.
7. Phua VJX, Yang CT, Xia B, Yan SX, Liu J, et al. Nanomaterial probes for nuclear imaging. Nanomaterials. 2022;12:582.
8. Fendler WP, Herrmann K, Eiber M. Nuclear medicine beyond VISION. J Nucl Med. 2021;62:916-917.
9. Filippi L, Chiaravalloti A, Schillaci O, Cianni R, Bagni O. Theranostic approaches in nuclear medicine: Current status and future prospects. Expert Rev Med Devices. 2020;17:331-343.
10. Czernin J, Sonni I, Razmaria A, Calais J. The future of nuclear medicine as an independent specialty. J Nucl Med. 2019;60:3-12.
11. Duan H, Iagaru A, Aparici CM. Radiotheranostics-precision medicine in nuclear medicine and molecular imaging. Nanotheranostics. 2022;6:103.
12. Farolfi A, Lima GM, Oyen W, Fanti S. Molecular imaging and theranostics—A multidisciplinary approach. Semin Nucl Med. 2019;49:247-254.
13. Xiao T, Li D, Shi X, Shen M. PAMAM Dendrimer-Based Nanodevices for Nuclear Medicine Applications. Macromol Biosci. 2020;20:1900282.
14. Könik A, O'Donoghue JA, Wahl RL, Graham MM, Van den Abbeele AD. Theranostics: the role of quantitative nuclear medicine imaging. Semin Radiat Oncol. 2021;31:28-36.
15. Vahidfar N, Aghanejad A, Ahmadzadehfar H, Farzanehfar S, Eppard E. Theranostic advances in breast cancer in nuclear medicine. Int J Mol Sci. 2021;22:4597.
16. Okamoto S, Shiga T, Tamaki N. Clinical perspectives of theranostics. Molecules. 2021;26:2232.
17. Lorenzoni A, Capozza A, Seregni E, Giovanella L. Nuclear medicine theranostics: between atoms and patients. Nucl Med Ther: Side Effects Complications. 2019;12:1-9.
18. Adnan A, Basu S. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET'score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. Nucl Med Commun. 2021;42:566-574.